-
Al Khatry, M., Abu Dayyeh, B.K. The Primary Obesity Surgery Endoluminal 2.0 Enfolding Technique (POSE 2.0et): Modification to Enhance Efficiency and Increase Restriction. [Article & Video] OBES SURG (2023). https://doi.org/10.1007/s11695-023-06569-4
Jirapinyo P, Thompson CC, A Comparison of Distal POSE Techniques for the Treatment of Obesity, Gastrointestinal Endoscopy (2022), https://doi.org/10.1016/j.gie.2022.04.1346.
Turro, R. Sabater, A., Feliz, Sterling & Mata, A, et al. (2023). The Endoscopic Mega Plication Procedure (EMPP). Prospective Study of the Primary Obesity Surgery Endoluminal (POSE) with Double G-Lix Procedure for treatment of Obesity. Safety and effectiveness at three-month follow-up. Endoscopy 2023; 55(S02) 158-158. https://doi.org/10.1055/s-0043-1765400.
-
Al Khatry, M., Abu Dayyeh, B.K. The Primary Obesity Surgery Endoluminal 2.0 Enfolding Technique (POSE 2.0et): Modification to Enhance Efficiency and Increase Restriction. [Article & Video] OBES SURG (2023). https://doi.org/10.1007/s11695-023-06569-4
Jirapinyo P, Thompson CC, A Comparison of Distal POSE Techniques for the Treatment of Obesity, Gastrointestinal Endoscopy (2022), https://doi.org/10.1016/j.gie.2022.04.1346.
Turro, R. Sabater, A., Feliz, Sterling & Mata, A, et al. (2023). The Endoscopic Mega Plication Procedure (EMPP). Prospective Study of the Primary Obesity Surgery Endoluminal (POSE) with Double G-Lix Procedure for treatment of Obesity. Safety and effectiveness at three-month follow-up. Endoscopy 2023; 55(S02) 158-158. https://doi.org/10.1055/s-0043-1765400.
USGI Medical has CE Mark Indication for the use of its devices for approximation of soft tissue in minimally invasive gastroenterology procedures, including use in obesity intervention for BMI 30 - 40.
In the United States, USGI Medical's devices are cleared by the FDA for approximation of soft tissue in minimally invasive gastroenterology procedures. The use of USGI Medical’s devices to treat obesity is currently under FDA Investigation.
USGI Medical has CE Mark Indication for the use of its devices for approximation of soft tissue in minimally invasive gastroenterology procedures, including use in obesity intervention for BMI 30 - 40.
In the United States, USGI Medical's devices are cleared by the FDA for approximation of soft tissue in minimally invasive gastroenterology procedures. The use of USGI Medical’s devices to treat obesity is currently under FDA Investigation.